| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.069 | 0.07 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | -0.29 | 0.07 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.064 | 0.07 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.079 | 0.07 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.06 | 0.07 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | -0.31 | 0.07 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | 0.054 | 0.07 |
| mRNA | 17-AAG | FIMM | pan-cancer | AAC | -0.31 | 0.07 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.093 | 0.07 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.07 |